Jeffrey G. Lamothe - Mar 3, 2023 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
EVP, COO
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Stock symbol
APVO
Transactions as of
Mar 3, 2023
Transactions value $
$0
Form type
4
Date filed
3/7/2023, 03:44 PM
Previous filing
Jan 30, 2023
Next filing
Aug 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +3.67K +40.62% 12.7K Mar 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -3.67K -33.33% $0.00 7.33K Mar 3, 2023 Common Stock 3.67K Direct F1, F2
transaction APVO Restricted Stock Unit Award $0 +16.5K $0.00 16.5K Mar 3, 2023 Common Stock 16.5K Direct F1, F3
transaction APVO Stock Option (right to buy) Award $0 +16.5K $0.00 16.5K Mar 3, 2023 Common Stock 16.5K $2.15 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On June 7, 2022, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023.
F3 The RSUs vest in three approximately equal annual installments beginning on March 2, 2024.
F4 The option vests in three approximately equal annual installments beginning on March 2, 2024.